Perspective - Journal of Medicinal and Organic Chemistry (2025) Volume 8, Issue 6
Lipid-Based Drug Delivery: Enhancing Therapeutic Efficiency and Targeting
Dr. Chloe Bennett*
Dept. of Pharmaceutics, Western Isles Univ, UK
- *Corresponding Author:
- Dr. Chloe Bennett
Dept. of Pharmaceutics, Western Isles Univ, UK
E-mail: cbennett@wiu.ac.uk
Received: 01-Dec-2025, Manuscript No. jmoc-26-184946; Editor assigned: 03- Dec -2025, PreQC No. jmoc-26-184946 (PQ); Reviewed: 18- Dec -2025, QC No. jmoc-26-184946; Revised: 21- Dec -2025, Manuscript No. jmoc-26-184946 (R); Published: 31- Dec -2025, DOI: 10.37532/jmoc.2025.7(6).295-307
Lipid-based drug delivery systems have emerged as a versatile and effective strategy to improve the bioavailability, stability, and targeting of therapeutic agents. By encapsulating drugs within lipid carriers, these systems can overcome challenges such as poor solubility, rapid metabolism, and limited tissue penetration. Lipid-based delivery platforms, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, are increasingly applied in pharmaceuticals, vaccines, and gene therapy, demonstrating significant potential to enhance treatment efficacy and patient outcomes [1-5].
Discussion
The fundamental advantage of lipid-based drug delivery lies in its biocompatibility and ability to mimic biological membranes. Lipid carriers can encapsulate hydrophilic, hydrophobic, and amphiphilic drugs, protecting them from enzymatic degradation and enhancing systemic circulation. Liposomes, spherical vesicles composed of phospholipid bilayers, have been widely used to deliver chemotherapeutics, antifungal agents, and nucleic acids. Their surface can be functionalized with ligands, antibodies, or polyethylene glycol (PEG) to improve target specificity, prolong circulation, and reduce immune clearance.
Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provide additional advantages, including controlled drug release, high physical stability, and scalability for industrial production. These platforms allow sustained release of drugs, reducing dosing frequency and improving patient compliance. Additionally, lipid-based carriers can cross biological barriers such as the blood-brain barrier or intestinal epithelium, expanding therapeutic possibilities for central nervous system disorders and oral drug delivery.
Recent advances in lipid-based delivery include stimuli-responsive systems that release drugs in response to pH, temperature, or enzymatic activity, enabling precise spatiotemporal control. The integration of lipid carriers with nucleic acid therapeutics, such as siRNA or mRNA vaccines, has transformed fields like oncology and infectious diseases, exemplified by the success of lipid nanoparticle-based COVID-19 vaccines. Computational modeling and high-throughput screening have further optimized lipid composition, size, and surface properties, enhancing efficacy and minimizing toxicity.
Challenges in lipid-based drug delivery include potential immunogenicity, formulation instability, and batch-to-batch variability. Addressing these requires careful lipid selection, robust manufacturing processes, and comprehensive preclinical evaluation.
Conclusion
Lipid-based drug delivery systems offer a biocompatible, versatile, and efficient platform for enhancing drug solubility, stability, and targeting. By enabling controlled release and improving tissue penetration, these systems have transformed therapeutic strategies in oncology, infectious diseases, and gene therapy. Continued innovation in lipid chemistry, formulation design, and stimuli-responsive technologies promises to expand their clinical applications, making lipid-based delivery an indispensable tool in next-generation pharmaceuticals.
References
- Selvaraj C, Chandra I, Singh SK (2021) Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Molecular diversity 1-21.
- Henstock P (2021) Artificial intelligence in pharma: positive trends but more investment needed to drive a transformation. Archives of Pharmacology and Therapeutics 2: 24-28.
- Mak KK, Pichika MR (2019) Artificial intelligence in drug development: present status and prospects. Drug Discovery Today 24: 773-780.
- Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, et al. (2023) Artificial intelligence in pharmaceutical and healthcare research. Big Data and Cognitive Computing 7: 10.
- Patil P, Nrip NK, Hajare A, Hajare D, Patil MK, et al. (2023) Artificial intelligence and tools in pharmaceuticals: An overview. Research Journal of Pharmacy and Technology 16: 2075-2082.
